Oncology Data Advisor: Welcome to the Oncology Data Advisor Fellows Forum. Today I have the pleasure of being joined by Dr. Richa Thakur, who is a Palliative Care Physician and a Hematology/Oncology Fellow at Zucker School of Medicine at Hofstra/Northwell Health. Dr. Thakur, thank you so much for coming on today. Richa Thakur, MD: Oh, thank you so much for having me. I'm really excited to be here. Oncology Data Advisor: Would you like you to introduce yourself and share what your work focuses on...

Oncology Data Advisor: Welcome to Oncology Data Advisor. Today we're here at ONS Congress, and I'm joined by Maria Badillo, who is on our Editorial Board. Thanks so much for coming on today, Maria. Maria Badillo, MSN, RN, OCN®, CCRP: Good morning, thank you for inviting me here today. I'm Maria Badillo. I'm a Research Nurse Manager at MD Anderson Cancer Center. Oncology Data Advisor: Awesome. How is it being back in person at ONS this year? Ms. Badillo: Oh, it's great. It's great to see people a...

Oncology Data Advisor® · Aligning Treatment Goals and Value-Based Care in Multiple Myeloma With Joseph Kalis, PharmD In this exclusive interview recorded with the Pharmacy Podcast Network, Dr. Joseph Kalis, an Ambulatory Oncology Clinical Pharmacy Specialist at the University of Colorado Health, shares an insightful preview of his continuing pharmacy education (CPE)–accredited activity on newly diagnosed multiple myeloma developed with i3 Health, as well as the potential for empo...

Oncology Data Advisor® · Creating Welcoming Spaces for LGBTQ+ Cancer Survivorship Care At the 48th Annual Oncology Nursing Society (ONS) Congress, Dr. Megan Mullins, an Assistant Professor at the University of Texas (UT) Southwestern Cancer Center, gave a presentation on improving cancer survivorship for sexual and gender minorities. In this follow-up interview, she shares the ongoing efforts into improving cancer survivorship care for these populations, as well as advice and resource...

Oncology Data Advisor: In this month of May dedicated to nurses, we have a very inspiring nurse practitioner with us today at Oncology Data Advisor: Dr. Lauren Ghazal, a Family Nurse Practitioner and a Post-Doctoral Research Fellow at the University of Michigan. Her research on work-related challenges and financial toxicity in adolescent and young adult cancer survivors is funded by the National Cancer Institute. Lauren is a cancer survivor, and she is the author of editorial articles featured o...

Oncology Data Advisor: Welcome to Oncology Data Advisor. Today, we're here at ONNS Congress, and I'm joined by Colleen Stoner and Diane Haley. Thank you both so much for coming on today. Colleen Stoner: Thank you. Diane Haley, LCSW: We are so happy to be with you. Oncology Data Advisor: Would you both like to introduce yourselves and share what you do? Ms. Haley: I'm Diane Haley. I am Director of Patient Experience at Rutgers Cancer Institute of New Jersey in New Brunswick, New Jersey. I have be...

Oncology Data Advisor: Welcome to Oncology Data Advisor. Today, I'm here at ONS Congress, and I'm joined by Colette Baudoin. Thanks so much for coming on today. Colette Baudoin, PhD (c), MSN, RN, OCN, CNE: Thank you for inviting me. Oncology Data Advisor: Would you like to introduce yourself and share what your work focuses on? Ms. Baudoin: Sure, so my name is Colette Baudoin. I am full-time faculty at Louisiana State University (LSU) Health Sciences Center and the New Orleans School of Nursing....

Oncology Data Advisor: Welcome to Oncology Data Advisor. Today, I'm joined by Tony Ellis, who is the Executive Director of the Oncology Nursing Certification Corporation. Thanks so much for coming on today, Tony. Tony Ellis, MSEd, CAE, ICE-CCP: Thanks for having me. Oncology Data Advisor: So, to start off, what is the mission of ONCC? Mr. Ellis: The primary purpose of ONCC is to promote health and safety by validating competence, knowledge, and experience, and by ensuring lifelong learning in on...

Oncology Data Advisor: Welcome to Oncology Data Advisor. Today, we're here at ONS Congress, and I'm joined by Dr. Amanda King. Thanks so much for coming on today. Amanda King, PhD, APNP-BC: Of course, happy to be here. Oncology Data Advisor: Would you like to introduce yourself and share what your work focuses on? Dr. King: Sure, my name is Dr. Amanda King, and I'm a Nurse Scientist at the National Institutes of Health (NIH). I work in the Neuro-Oncology Branch and the Office of Patient-Centered...

Oncology Data Advisor: Welcome to Oncology Data Advisor. Today, I'm here at ONS Congress, and I'm joined by Amy Rettig. Thank you so much for joining me. Amy Rettig, DNP, RN, APRN-BC: Thank you. I'm very happy to be here, Keira. Oncology Data Advisor: Would you like to introduce yourself and share what your work focuses on? Dr. Rettig. Sure, my name is Amy Rettig, and I work as a Mental Health Advanced Practice Registered Nurse at the James Cancer Hospital at The Ohio State University. My work f...

Oncology Data Advisor: Welcome to Oncology Data Advisor. Today, we're here at ONS Congress, and I'm joined by Elizabeth Archer-Nanda and Meagan Dwyer. Thank you both so much for joining me. Elizabeth Archer-Nanda, DNP, PMHCNS-BC: Thanks, Keira. I'm Elizabeth Archer-Nanda. I'm a Psychiatric Clinical Nurse Specialist at Norton Cancer Institute in Louisville, Kentucky, and the Immediate Past President of the American Psychosocial Oncology Society (APOS). Meagan Dwyer, PhD: Yes, thanks so much for h...

Oncology Data Advisor: Welcome to Oncology Data Advisor. Today, we're here at ONS Congress and I'm joined by Nick Escobedo. Thank you so much for coming on today. Nick Escobedo, DNP, RN, OCN, NE-BC: Thank you for having me. Oncology Data Advisor: Would you like to introduce yourself and share what your work is focusing on? Dr. Escobedo: Yes, of course. So, as you said, I am Nick Escobedo, I've been an Oncology Nurse for just about 13 years. I've had various kinds of practice settings in my few y...

Oncology Data Advisor® · Live Podcasts From the 2023 Oncology Nursing Society (ONS) Congress: Part 1 At the 48th Annual Oncology Nursing Society (ONS) Congress in San Antonio, Texas, Oncology Data Advisor had the privilege of interviewing many distinguished nursing speakers about their research. This ONS Congress playlist features podcast conversations on topics including the healing power of therapy dogs, the benefits of virtual reality for patients with cancer, strategies for bolste...

Oncology Data Advisor: Welcome to Oncology Data Advisor. Today I'm here at ONS Congress, and I'm joined by Scott Christensen. Thanks so much for joining me. Scott Christensen, DNP, MBA, APRN, ACNP-BC: Thank you very much. I'm happy to be here. Oncology Data Advisor: Would you'd like to introduce yourself and share what your research focus is on? Dr. Christensen: Sure. I work at the University of Utah Health. I am a Nurse Administrator. I'm also an Adjunct with the College of Nursing, and I'm hel...

Oncology Data Advisor: Welcome to the Oncology Data Advisor Fellows Forum, I'm Keira Smith. Today I'm joined by Dr. Sunil Iyer, who is a Chief Hematology/Oncology Fellow at the University of Miami. Dr. Iyer, thank you so much for coming on today. Sunil Iyer, MD: Hi everyone. It's an honor to be here. I'm Sunil Iyer. I'm a third-year Hematology/Oncology Fellow, current Chief Fellow for the next month and a half, at the University of Miami Sylvester Comprehensive Cancer Center in Miami, Florida. I...

Oncology Data Advisor: Welcome to Oncology Data Advisor. I'm Keira Smith. This April, we're excited to be celebrating National Minority Health Month. Today, I'm joined by Dr. Shakira Grant, who will be sharing her research in the field of health care disparities. Dr. Grant, thank you so much for coming on today. Shakira Grant, MBBS: Hi, I'm Dr. Shakira Grant. I'm an Assistant Professor at the University of North Carolina at Chapel Hill. I spend my time primarily engaged in patient-centered resea...

Oncology Data Advisor: Welcome to Oncology Data Advisor, I'm Keira Smith. Today I'm joined by Dr. Lisa Gudenkauf, who is an Applied Research Scientist in Health Outcomes and Behavior at Moffitt Cancer Center. She's here today to discuss her research regarding patient-reported outcomes for prostate cancer, which was recently presented at the ASCO Genitourinary Cancers Symposium. Dr. Gudenkauf, thank you so much for coming on today. Lisa Gudenkauf, PhD: Hi, my name is Lisa Gudenkauf. I'm an Applie...

Oncology Data Advisor™ · Do Accelerated Approvals Really Benefit Patients? With Ravi Parikh, MD, MPP Recently, Ravi Parikh, MD, MPP, an Assistant Professor of Medical Ethics and Health Policy and Medicine at the University of Pennsylvania, Perelman School of Medicine, released a research letter titled, "Exposure to US Cancer Drugs With Lack of Confirmed Benefit After US Food and Drug Administration Accelerated Approval." In this interview with OncData, he further discusses his resea...

Oncology Data Advisor: Hi everybody. Welcome to Oncology Data Advisor. Today, we're holding a panel discussion with our Editorial Board in honor of Rare Disease Day. I'm joined by our Editor-in-Chief, Dr. Thomas Abrams, who is an Assistant Professor of Medicine at Harvard Medical School and Institute Physician at Dana-Farber Cancer Institute, and he'll be discussing rare gastrointestinal cancers. Dr. Abrams, thanks for joining today. Thomas Abrams, MD: Oh, it's my pleasure. This is really exciti...

Oncology Data Advisor: Welcome to Oncology Data Advisor, I'm Keira Smith. Today, I'm joined by Dr. Ticiana Leal. Last year, Dr. Leal chaired a CME/NCPD activity focused on immunotherapy-based strategies for advanced non–small cell lung cancer. Today, she'll be sharing the updates that have occurred in the field since recording this activity. Thanks so much for joining today, Dr. Leal. To start off, would you like to introduce yourself and tell us about what you do? Ticiana Leal, MD: Hi, I'm Dr. ...

This podcast episode was recorded live by Oncology Data Advisor and ConveyMED at the 2022 ASH Annual Meeting in New Orleans. Oncology Data Advisor: Welcome to Oncology Data Advisor. Today we're at the ASH Annual Meeting, and I'm here with Dr. Yimer, who is here to talk about his brentuximab vedotin study for advanced-stage classical Hodgkin lymphoma. Thanks so much for joining today. Habte Yimer, MD: Thank you for inviting me. Oncology Data Advisor: So, would you like to tell us a little bit abo...

This podcast episode was recorded live by Oncology Data Advisor and ConveyMED at the 2022 ASH Annual Meeting in New Orleans. Oncology Data Advisor: Welcome to Oncology Data Advisor. Today, we're here at the ASH Annual Meeting and I'm here with Dr. Ira Zackon. Thanks so much for joining today. Ira Zackon, MD: It's a pleasure, thank you for having me. Oncology Data Advisor: Would you like to tell us a little bit about yourself and about what you do? Dr. Zackon: Sure. I've been a practicing Hematol...

This podcast episode was recorded live by Oncology Data Advisor and ConveyMED at the 2022 ASH Annual Meeting in New Orleans. Oncology Data Advisor: Welcome to Oncology Data Advisor. I'm Keira Smith. Today, I'm here at the ASH Annual Meeting with Dr. Shernan Holtan, who is here to talk about the results of the BMT CTN 1703 trial that she is presenting. Shernan Holtan, MD: Thanks for having me. We're really lucky to be able to present the 1703 data. This is a phase 3 clinical trial that literally ...

This podcast episode was recorded live by Oncology Data Advisor and ConveyMED at the 2022 ASH Annual Meeting in New Orleans. Oncology Data Advisor: Welcome to Oncology Data Advisor. Today, I'm at the ASH Annual Meeting with Dr. Oluwole, who is here to talk about his research. Thank you for being here. Ola Oluwole, MD: Thank you. Oncology Data Advisor: I believe you have two abstracts here. Would you like to tell us a little bit about these? Dr. Oluwole: Yes, the first abstract I'm going to talk ...

This podcast episode was recorded live by Oncology Data Advisor and ConveyMED at the 2022 ASH Annual Meeting in New Orleans. Oncology Data Advisor: Welcome to Oncology Data Advisor. Today, we're here at the ASH Annual Meeting and I'm with Dr. Mitul Gandhi. Thanks so much for being here. Mitul Gandhi, MD: My pleasure. Oncology Data Advisor: Would you like to introduce yourself and tell us about what you do? Dr. Gandhi: Sure, my name is Mitul Gandhi. I'm a Medical Oncologist and Hematologist, part...

This podcast episode was recorded live by Oncology Data Advisor and ConveyMED at the 2022 ASH Annual Meeting in New Orleans. Oncology Data Advisor: Welcome to Oncology Data Advisor. Today, we're here at the ASH Annual meeting, and I'm here with Dr. Lee from MD Anderson. Thanks so much for being here. Hun Lee, MD: Thank you so much for this invitation, Keira. Oncology Data Advisor: Would you like to tell us about yourself and your research? Dr. Lee: My name is Hun. I am an Associate Professor at ...

This podcast episode was recorded live by Oncology Data Advisor and ConveyMED at the 2022 ASH Annual Meeting in New Orleans. Oncology Data Advisor: Welcome to Oncology Data Advisor. Today, we're here at the ASH Annual Meeting, and I'm here with Dr. Ariela Marshall. Thank you so much for being here. Ariela Marshall, MD: Absolutely. Thanks for the opportunity to talk with you guys. Oncology Data Advisor: I believe you are the Co-Chair of the ASH Women in Hematology Working Group. Would you like to...

This podcast episode was recorded live by Oncology Data Advisor and ConveyMED at the 2022 ASH Annual Meeting in New Orleans. Oncology Data Advisor: Welcome to Oncology Data Advisor. Today we're here at the ASH Annual Meeting, and I'm here with Dr. Shakira Grant. Thanks so much for being here. Shakira Grant, MBBS: Thank you so much for having me. Oncology Data Advisor: Would you like to tell us a little bit about yourself and about what you do? Dr. Grant: Sure. I am currently an Assistant Profess...

This podcast episode was recorded live by Oncology Data Advisor and ConveyMED at the 2022 ASH Annual Meeting in New Orleans. Oncology Data Advisor. Welcome to Oncology Data Advisor. Today I'm here with Dr. Ian Bouligny, who is here to talk about his abstract on health care disparities in AML treatment. Thanks much for being here today. Ian Bouligny, MD: Yes, thank you very much. Thanks for having me, I appreciate it. Oncology Data Advisor: Would you like to tell us a little bit about yourself an...

This podcast episode was recorded live by Oncology Data Advisor and ConveyMED at the 2022 ASH Annual Meeting in New Orleans. Oncology Data Advisor: Welcome to Oncology Data Advisor. Today, we're at the ASH Annual Meeting, and I'm here with Ronak Mistry and Vivek Patel. Thank you both so much for being here. Ronak Mistry, DO: It's a pleasure to be here, and thank you so much for inviting us. Vivek Patel, MD: Yes, thanks for having us. Oncology Data Advisor: Absolutely. So, would you like to intro...

This podcast episode was recorded live by Oncology Data Advisor and ConveyMED at the 2022 ASH Annual Meeting in New Orleans. Oncology Data Advisor: Welcome to Oncology Data Advisor. I'm Keira Smith, and today, I'm here with Luis Gerardo Rodríguez-Lobato at the ASH Annual Meeting. Thank you so much for being here today. Luis Gerardo Rodríguez-Lobato, MD, PhD: Hello Keira, nice to meet you also. I'm very pleased to be here with you at the ASH meeting. Oncology Data Advisor: Yes. So, tell us about ...

This podcast episode was recorded live by Oncology Data Advisor and ConveyMED at the 2022 ASH Annual Meeting in New Orleans. Oncology Data Advisor: Welcome to Oncology Data Advisor. Today, we're at the ASH Annual Meeting, and I'm here with Dr. Robert Rifkin. Dr. Rifkin, thank you so much for joining today. Robert Rifkin, MD, FACP: Thank you very much, and I'm delighted to be here. I'm Robert Rifkin, I'm a Medical Oncologist at Rocky Mountain Cancer Centers in Denver, Colorado, and I'm the Diseas...

This podcast episode was recorded live by Oncology Data Advisor and ConveyMED at the 2022 ASH Annual Meeting in New Orleans. Oncology Data Advisor: Welcome to Oncology Data Advisor. Today we're here at the ASH Annual Meeting, and I'm joined by Dr. Samer Al Hadidi, who's here to talk about two of his studies. Thanks so much for joining today. Samer Al Hadidi, MD, MS, FACP: Thank you for having me. I'm Samer Al Hadidi. I'm an Assistant Professor at the University of Arkansas, where I practice and ...

Oncology Data Advisor: Welcome to Oncology Data Advisor, I'm Keira Smith. Today I'm joined by Dr. Tabernero, who is here to talk about the results of the phase 3 SUNLIGHT trial being presented at the ASCO Gastrointestinal (GI) Cancers Symposium. Dr. Tabernero, thanks so much for joining me today. Josep Tabernero, MD, PhD: Absolutely. My name is Josep Tabernero. I'm a Medical Oncologist based in Barcelona at the Vall d'Hebron Institute of Oncology. My special focus has been always the treatment o...

This podcast episode was recorded live by Oncology Data Advisor and ConveyMED at the 2022 ASH Annual Meeting in New Orleans. Oncology Data Advisor: Welcome to Oncology Data Advisor. Today, we're here at the ASH Annual Meeting, and I'm here with Dr. Chari, who is here to discuss the MonumenTAL-1 study. Thanks so much for being here. Ajai Chari, MD: Thank you for having me. It's a pleasure. Oncology Data Advisor: Would you like to tell us a little bit about yourself and about what you do? Dr. Char...

This podcast episode was recorded live by Oncology Data Advisor and ConveyMED at the 2022 ASH Annual Meeting in New Orleans. Oncology Data Advisor: Welcome to Oncology Data Advisor. We're here at the ASH Annual Meeting today, and I'm with Dr. Luke Walker, who is the Chief Medical Officer of Harpoon Therapeutics. Thanks for joining today. Luke Walker, MD: Thanks so much for having me. Oncology Data Advisor: Would you like to tell us a little bit about yourself and your background? Dr. Walker: Sur...

Oncology Data Advisor™ · Discussing the Relevance of Urine Studies in Myeloma With Kelsey Natsuhara, MD At the recent American Society of Hematology (ASH) Annual Meeting, Kelsey Natsuhara, MD, a Fellow in Hematology and Oncology at the University of California, San Francisco, sat down with Oncology Data Advisor and ConveyMED to discuss her presentation regarding the relevance of urine studies in myeloma patients undergoing transplantation. This podcast episode was recorded live by O...

This podcast episode was recorded live by Oncology Data Advisor and ConveyMED at the 2022 ASH Annual Meeting in New Orleans. Oncology Data Advisor: Welcome to Oncology Data Advisor. Today, we're at the ASH Annual Meeting, and I'm here with Manni Mohyuddin. Thank you so much for joining today. Manni Mohyuddin, MBBS: The pleasure is mine, thank you. Oncology Data Advisor: So, I know you have a few abstracts here at the meeting. Would you like to tell us about these and give a little overview of th...

Oncology Data Advisor: Welcome to Oncology Data Advisor, I'm Keira Smith. Today I am joined by Dr. Amir Fathi, an Associate Professor of Medicine at Harvard Medical School. He is going to be sharing some of the significant updates in acute myeloid leukemia and acute lymphoblastic leukemia from the recent ASH Annual Meeting. Dr. Fathi, thanks so much for joining me today. Amir Fathi, MD: Sure, my name is Amir Fathi. I'm an academic oncologist. I work at Massachusetts General Hospital. I direct th...

Oncology Data Advisor: Welcome to Oncology Data Advisor, I'm Keira Smith. Today, I'm joined by Dr. Mark Kris, who is the William and Joy Ruane Chair in Thoracic Oncology at Memorial Sloan Kettering Cancer Center. Dr. Kris will be sharing the updates that have occurred in metastatic squamous non–small cell lung cancer treatment during this past year. Dr. Kris, thanks so much for being here today. Mark Kris, MD: Hello, I'm Mark Kris. I'm a thoracic medical oncologist, and I work at Memorial Sloan ...

Transcript edited for clarity. Any views expressed above are the speaker's own and do not necessarily reflect those of Oncology Data Advisor.  Oncology Data Advisor: Welcome to Oncology Data Advisor, I'm Keira Smith. Today, I have the honor of being joined by Dr. Irving Weissman, a Professor of Pathology and Developmental Biology and the Director of the Institute of Stem Cell Biology and Regenerative Medicine at Stanford University. Recently, Dr. Weissman received the Wallace H. Coulter Awa...

Oncology Data Advisor: Welcome to Oncology Data Advisor, I'm Keira Smith. Today I'm joined by Dr. Shaji Kumar, Professor of Hematological Malignancies at the Mayo Clinic Cancer Center. Dr. Kumar, thank you so much for joining me today. Since the ASH Annual Meeting just happened recently, would you like to tell us about the abstracts that you presented there? Shaji Kumar, MD: One of the abstracts that we have presented was on the long-term follow-up of the MAIA study. That is a phase 3 trial look...

Oncology Data Advisor™ · Additional Advancements in Research: Multiple Myeloma Earlier this year, Dr. Sarah Holstein of the University of Nebraska Medical Center participated in a two-part continuing medical education (CME) activity regarding practice-changing strategies and improved patient outcomes in the treatment of multiple myeloma (MM). With many updates and improvements in the treatment of MM since recording, Dr. Holstein joins OncData to share her knowledge and talk about wh...

Oncology Data Advisor: Welcome to Oncology Data Advisor. Today I'm joined by Dr. Brian Koffman, who is the founder of CLL Society. Dr. Koffman, thank you so much for being here today. Brian Koffman, MD: My great pleasure, thank you. Oncology Data Advisor: To start off, would you like to tell us a little bit about yourself and your background and how you came to establish CLL Society? Dr. Koffman: Absolutely, thanks. I'm Dr. Brian Koffman. I'm a retired family doctor, and I was diagnosed in 2005 ...

Oncology Data Advisor: Welcome to Oncology Data Advisor. Today, I'm here with Dr. Christopher Iannuzzi, who is the Medical Director of Physician Services and the Chair of Oncology at Hartford HealthCare, St. Vincent's Medical Center. Dr. Iannuzzi is the Principal Investigator of an ongoing clinical trial for advanced prostate cancer at Hartford HealthCare, and today he's going to tell us some more about this trial, as well as some other advice for prostate cancer screening in light of Men's Heal...

Oncology Data Advisor: Welcome to Oncology Data Advisor. Today, I am joined by Dr. Morie Gertz from the Mayo Clinic in Minnesota. Last year, Dr. Gertz chaired an activity for i3 Health focusing on Waldenstrom macroglobulinemia. Today, he's here to talk about the updates in the field that have occurred since then. Dr. Gertz, thank you so much for being here today. Morie Gertz, MD: Good morning. You bet. Oncology Data Advisor: Since this activity was recorded last January, what are the additional ...

Rahul Banerjee, MD, FACP: Hi, everyone. Welcome to Oncology Data Advisor, your resource for the multidisciplinary cancer team. My name is Dr. Rahul Banerjee, and I'm on the Editorial Board for Oncology Data Advisor. Today, it is my pleasure to speak with Dr. Meier and Dr. Rubinstein about clonal hematopoiesis in hematologic malignancies as we speak about Blood Cancer Awareness Month. Dr. Meier is a Fellow in the Division of Hematology and Oncology at UNC Chapel Hill. His research interests are i...

Oncology Data Advisor: Welcome to Oncology Data Advisor, I'm Keira Smith. Today I'm here with Dr. Valerie Brutus, who is a Breast Surgical Oncologist at St. Vincent's Medical Center of Hartford HealthCare in Connecticut. Since October is Breast Cancer Awareness Month, I know that one of the areas that you're passionate about is breast cancer in transgender patients. Would you like to talk to us a little bit about the risk factors and the screening recommendations for this population? Valerie Bru...

Oncology Data Advisor: Welcome to Oncology Data Advisor, I'm Keira Smith. Today I'm here with Dr. Elizabeth Stirling Craig, who is the Director of Microvascular Breast Reconstruction at St. Vincent's Medical Center of Hartford HealthCare. Thank you so much for joining us today. Elizabeth Stirling Craig, MD: Sure, my name is Dr. Stirling Craig and I'm currently the Director of Microvascular Breast Reconstruction for the Hartford HealthCare System. My background is that I'm a plastic surgeon who d...

Oncology Data Advisor™ · Blood Cancer Awareness Month: Exploring Patient-Reported Outcomes: Rahul Banerjee and Ajay Major Recently, Dr. Rahul Banerjee, Assistant Professor at the University of Washington and Editorial Board member for Oncology Data Advisor, spoke with Dr. Ajay Major, Assistant Professor at the University of Colorado, in a live interview discussion in honor of Blood Cancer Awareness Month. Dr. Banerjee and Dr. Major engaged in a riveting conversation about the role o...

Oncology Data Advisor: Welcome to Oncology Data Advisor. Today I'm speaking with Blanca Ledezma, who is a Nurse Practitioner at the University of California, Los Angeles (UCLA) Santa Monica. Thank you so much for joining us today. Blanca Ledezma, MSN, NP: I'm Blanca Ledezma. I'm a Nurse Practitioner here in Santa Monica at UCLA Outpatient Oncology. I've been a Nurse Practitioner for over 18 years. My focus is thoracic malignancies. I work with both the clinical research and with the standard of ...

Oncology Data Advisor: Welcome to Oncology Data Advisor. I'm Keira Smith. Today I'm here with Dr. Joshua Sasine, who is here to share his advice on caring for patients receiving CAR T-cell therapy. Thank you so much for joining us today. Joshua Sasine, MD, PhD: Sure, I'm a Hematologist-Oncologist and I work at Cedars-Sinai Medical Center. I'm interested in cellular therapies. I routinely do bone marrow transplants and treat patients with CAR T cells. I'm also a physician-scientist, and I have a ...

Oncology Data Advisor: Welcome to Oncology Data Advisor. Today I'm here with Dr. Valerie Brutus, a Breast Surgical Oncologist at St. Vincent's Medical Center of Hartford Healthcare in Connecticut. Thank you for joining me today. Valerie Brutus, MD, FACS: Thank you so much for having me. Oncology Data Advisor: Of course. Tell us about this new technology, Magtrace. What is it, and how does it work? Dr. Brutus: Magtrace is a magnetic dye, and when it's injected into the breast, it mimics what brea...

Oncology Data Advisor: Welcome to Oncology Data Advisor. Today, we're here doing a live interview in honor of World Lung Cancer Day. I'm joined by Beth Sandy, who's one of our editorial board members, as well as Dr. Corey Langer. Thank you both for joining us. Would you like to introduce yourselves? Beth Sandy, MSN, CRNP: I'm Beth Sandy. I'm a Nurse Practitioner in the Cancer Center at the University of Pennsylvania in Philadelphia, and my primary practice specialty is lung cancer. With me, I ha...

Oncology Data Advisor: Welcome to Oncology Data Advisor. Today I'm here with Dr. Ash Alpert. Thank you so much for joining us. Ash Alpert, MD, MFA: I'm Dr. Ash Alpert. I'm a postdoctoral fellow in health services research at Brown University, and I'm a hematologist and medical oncologist. My research focuses on improving the experiences and outcomes of transgender people with cancer. Oncology Data Advisor: Would you like to tell us a little bit about the two posters that you presented at ASCO re...

Oncology Data Advisor: Welcome to Oncology Data Advisor. I am here with Dr. Ian Krop of Yale University who presented data on the novel HER3-targeting antibody-drug conjugate patritumab deruxtecan in HER3-expressing metastatic breast cancer. Thank you for joining us, Dr. Krop. Ian Krop, MD, PhD: I'm happy to be here. And just so you know, we all call it just HER3-DXd, which is a lot easier to say than patritumab deruxtecan. Oncology Data Advisor: Thank you. Why is there so much excitement about ...

Oncology Data Advisor: Hi, welcome to Oncology Data Advisor. I'm Beth Heller, and I'm here with Dr. London from the Dana-Farber Cancer Institute and Boston Children's Hospital. She is presenting her research at the ASCO 2022 Annual Meeting. Dr. London, can you please tell us a bit about your research? Wendy London, PhD: Yes, I'd be happy to. Thank you very much for inviting me to come in and talk to you today. I am an Associate Professor of Pediatrics at Harvard Medical School, and I began worki...

Oncology Data Advisor: Welcome to Oncology Data Advisor, I'm Keira Smith. Today, I'm here at the ASCO Annual Meeting in Chicago speaking with Jason Mouabbi from MD Anderson Cancer Center. Thank you so much for joining us today. Jason Mouabbi, MD: Thank you, happy to be here. Oncology Data Advisor: Would you like to tell us a little bit about your poster here? Dr. Mouabbi: Yes, sure. At MD Anderson, I'm responsible for lobular breast cancer. I'm an expert in that field. Recently, we have shown in...

Oncology Data Advisor: Welcome to Oncology Data Advisor, I'm Keira Smith. Today, I'm here at the ASCO Annual Meeting in Chicago, speaking with Megan-Claire Chase of SHARE Cancer Support. Megan-Claire, thank you so much for being with us today. Megan-Claire Chase: Thank you so much. I'm so excited. Oncology Data Advisor: So, would you like to tell us a little bit about your story? Ms. Chase: Yes. So, my story begins like this; I always knew I would get cancer, and that's not because I'm a pessimi...

Oncology Data Advisor: Welcome to Oncology Data Advisor, I'm Keira Smith. Today, I'm here at the ASCO Annual Meeting in Chicago, speaking with Urvi Shah from Memorial Sloan Kettering Cancer Center (MSKCC). Thank you for joining us. Would you like to tell us a little bit about yourself? Urvi Shah, MD: Sure. I'm a Hematologist and Oncologist on the Myeloma Service at Memorial Sloan Kettering Cancer Center. I'm happy to be here to talk to you all. Oncology Data: I know you moderated the poster disc...

Oncology Data Advisor™ · Exploring the Impact of Cemiplimab and Pembrolizumab in Cutaneous Squamous Cell Carcinoma In honor of Melanoma Awareness Month, Oncology Data Advisor spoke with Dr. Shaheer Khan, an Assistant Professor of Medicine at Columbia University Irving Medical Center. Dr. Khan shares the promising results of two recent trials of cemiplimab and pembrolizumab for cutaneous squamous cell carcinoma, explains future directions in the treatment of patients who are ineligib...

Maria Badillo, MSN, RN, OCN®, CCRP: Good afternoon, Sherry. How are you doing? Sherry Adkins, MSN, APN-C: Great, Maria. How are you? Ms. Badillo: I'm good. Happy Nurses Week. Ms. Adkins: Thank you, you too. Ms. Badillo: Before we start our interview, I would like to give you a little background about Sherry. Sherry is an advanced practice nurse with over 20 years of experience. She completed her advanced practice oncology fellowship at the University of Texas Health Sciences 14 years ago, and th...

Oncology Data Advisor™ · Taking a Nuanced Approach to Testicular Cancer Management With Sam Kaffenberger, MD For this interview in honor of Testicular Cancer Awareness Month, Dr. Sam Kaffenberger, an Assistant Professor of Urology at the University of Michigan Health System, explains the importance of taking a nuanced approach to the management of individual patients with testicular cancer, with the goal of minimizing toxicity and achieving the best possible outcomes for treatment a...

Oncology Data Advisor™ · Can Digital Health Tools Improve Quality of Life in Multiple Myeloma? In this interview in honor of Multiple Myeloma Awareness Month, Dr. Rahul Banerjee, a Clinical Fellow in Medicine at the University of California, San Francisco, and member of the Oncology Data Advisor Editorial Board, speaks with Dr. Neha Korde of Memorial Sloan Kettering Cancer Center about the potential of digital health tools to improve quality of life for patients with multiple myelom...

Oncology Data Advisor™ · Exploring Recent Advances in Testicular Cancer Surgery and Access to Care This interview in honor of Testicular Cancer Awareness Month features Dr. Andrew Winer, Chief of Urology at Kings County Hospital in New York. Dr. Winer discusses the ongoing research regarding new approaches for testicular cancer surgery, strategies to address disparities in health care access for underserved populations, and the importance of taking a multidisciplinary approach to ac...

Oncology Data Advisor™ · Personalizing the Approach to Testicular Cancer Management With Aditya Bagrodia, MD, FACS This interview in honor of Testicular Cancer Awareness Month features Dr. Aditya Bagrodia, an Associate Professor of Urology at the University of California, San Diego. Dr. Bagrodia explains the factors that should be considered when selecting treatment options—including surgery, chemotherapy, radiation, or surveillance—for patients with testicular cancer, the future of...

Oncology Data Advisor™ · Considering VTE Risk Factors and Prophylaxis in Myeloma: Rajshekhar Chakraborty and Rahul Banerjee In this interview in honor of Multiple Myeloma Awareness Month, Dr. Rahul Banerjee, a Clinical Fellow in Medicine at the University of California, San Francisco, and member of the Oncology Data Advisor Editorial Board, speaks with Dr. Rajshekhar Chakraborty of Columbia University Irving Medical Center about risk factors for the development of venous thromboembo...

Oncology Data Advisor™ · Can Diet and Nutrition Impact Multiple Myeloma Outcomes? Urvi Shah and Rahul Banerjee In honor of Multiple Myeloma Awareness Month, Dr. Rahul Banerjee, Assistant Professor at the University of Washington and Fred Hutchinson Cancer Center, and member of the Oncology Data Advisor editorial board, speaks with Dr. Urvi Shah about the importance of ensuring proper diet and nutrition, as well as the impact of the microbiome, for patients with multiple myeloma. Rah...

Oncology Data Advisor™ · The Groundbreaking Approval of Tebentafusp for Uveal Melanoma With Richard Carvajal, MD Recently, the FDA granted approval to tebentafusp for the treatment of patients with human leukocyte antigen (HLA)-A*02:01–positive unresectable or metastatic uveal melanoma, marking the first agent to be approved for this rare ocular malignancy. In this interview, Dr. Richard Carvajal, Associate Professor of Medicine at Columbia University Irving Medical Center and edito...

Oncology Data Advisor™ · Advocating for Patients in Multiple Myeloma Clinical Trials: Manni Mohyuddin and Rahul Banerjee In this interview in honor of Multiple Myeloma Awareness Month, Dr. Rahul Banerjee, an Assistant Professor at the University of Washington and Fred Hutchinson Cancer Center, and member of the Oncology Data Advisor Editorial Board, speaks with Dr. Manni Mohyuddin about the importance of designing clinically relevant end points for clinical trials in multiple myelom...

Oncology Data Advisor: Welcome to Oncology Data Advisor. Today I'm here with Dr. Augusto Villanueva. Thank you so much for joining us today. Augusto Villanueva, MD, PhD: It's great to be here with you. Oncology Data Advisor: Could you tell us a little bit about what you do at Mount Sinai? Dr. Villanueva: I'm a hepatologist by training, but I've been doing research in HCC for the last 15 years, focusing on biomarker development, early detection, biomarkers of treatment response, and using liquid ...

This interview has been conducted in partnership with AAMDSIF, the world's leading nonprofit health organization dedicated to supporting patients and families living with aplastic anemia, MDS, paroxysmal nocturnal hemoglobinuria, and related bone marrow failure diseases. The Foundation provides answers, support, and hope to thousands of patients and their families around the world. Oncology Data Advisor: Welcome to Oncology Data Advisor. In honor of Rare Disease Day, I'm here today with Dr. Amy ...

Oncology Data Advisor: Hi, everyone. Thank you so much for joining us. Today we're here in honor of World Cancer Day with our Editor in Chief, Dr. Thomas Abrams, who is an Assistant Professor of Medicine at Harvard Medical School, as well as two of our editorial board members, Dr. Ulka Vaishampayan, a Professor of Medicine at the University of Michigan Rogel Cancer Center, and Beth Sandy, an outpatient thoracic oncology nurse practitioner at the University of Pennsylvania Abramson Cancer Center....

Oncology Data Advisor: Welcome to Oncology Data Advisor. Today I'm here with Dr. Kelly Brassil of the University of Texas MD Anderson Cancer Center and Dr. Rahul Banerjee from the University of California, San Francisco. Rahul Banerjee, MD: Thank you for having us. As we'll talk about, this is a really exciting area of research interplay between digital health supportive care and bone marrow transplantation, but it's not the traditional route of research that a lot of institutions engage upon. I...

Oncology Data Advisor: Welcome to Oncology Data Advisor. Today I'm here with Dr. Thomas Abrams, our Editor in Chief. Dr. Abrams, thank you so much for joining us today. Thomas Abrams, MD: It's my pleasure. Oncology Data Advisor: So can you give us an overview of the COSMIC-021 trial and the results that your team found? Dr. Abrams: Sure. This is a very preliminary trial. It's one cohort of a larger multicancer trial looking at a specific pair of drugs. One drug is called cabozantinib, which is a...

Oncology Data Advisor: I'm Keira Smith with Oncology Data Advisor. Today I'm here with Dr. Matthew Davids. Matthew Davids, MD, MMSc: Hello, I'm Matthew Davids. I'm an Associate Professor of Medicine at Harvard Medical School, and I direct the Clinical Research Program in the Division of Lymphoma at Dana-Farber Cancer Institute in Boston. Oncology Data Advisor: When a patient is told they have a p53 mutation and they ask you about p53 biology, what are some of the most important points to counsel...

Oncology Data Advisor: Welcome to Oncology Data Advisor. Today I'm here with Dr. Sumit Gupta. By way of background, why is research in racial, ethnic, and socioeconomic health disparities important? Sumit Gupta, MD: I think there's been an increasing awareness over, well, decades, but it's reached more prominence in recent times—in general, disparities in all of those parameters in medicine. I think there are areas of medicine such as childhood ALL where we are fortunate that we actually do pret...

Oncology Data Advisor: Welcome to Oncology Data Advisor. Today I'm here with Dr. Brigid Killelea. Brigid Killelea, MD, FACS: Hi, my name is Brigid Killelea. I am a breast surgical oncologist. I focus my practice on patients with benign and malignant breast disease. This includes women who have breast cancer; women who are at high risk for breast cancer, either because of their own history or family history; and those that have benign diseases of the breast. I practice in Bridgeport, Connecticut,...

Oncology Data Advisor: Welcome to Oncology Data Advisor. I'm here today with Dr. Richard Zelkowitz. Dr. Zelkowitz, could you tell us a little bit about what you do at Hartford HealthCare? Richard Zelkowitz, MD: I've been in town for about 32 years. I came in 1989, and my practice has been limited to breast cancer for probably 20 to 25 years. I'm a clinician, so most of what I do is clinical work. I'm very interested in clinical research and putting people on trials. I have seen a lot in 30 years...

Welcome to Oncology Data Advisor. For this live panel discussion in honor of breast cancer awareness month, I'm here today with Christine Samuel, an advanced practice provider at MD Anderson Cancer Center; Mikel Ross, a nurse practitioner at Memorial Sloan Kettering Cancer Center; and Lillie Shockney, a Professor of Surgery at Johns Hopkins University. Thank you all for joining us. We're excited to have a great discussion today. Oncology Data Advisor: Hi, everyone. Welcome to Oncology Data Advis...

This interview has been conducted in partnership with the National Breast Cancer Foundation (NBCF). Recognized as one of the leading breast cancer organizations in the world, NBCF is Helping Women Now® by providing early detection, education, and support services to those affected by breast cancer. A recipient of Charity Navigator's highest 4-star rating for 14 years, NBCF provides support through their National Mammography Program, Patient Navigation, breast health education, and patient suppor...

Oncology Data Advisor™ · Breast Cancer and Pandemic Challenges With Lillie Shockney, RN, BS, MAS, HON-ONN-CG Although the management of breast cancer has been impacted by the COVID-19 pandemic, the cancer care team has developed strategies to optimize screening and treatment experiences in spite of these challenges. In this interview, Lillie Shockney, RN, BS, MAS, HON-ONN-CG, Professor of Surgery at Johns Hopkins University and member of the National Breast Cancer Foundation Medical...

This interview has been conducted in partnership with the National Breast Cancer Foundation (NBCF). Recognized as one of the leading breast cancer organizations in the world, NBCF is Helping Women Now® by providing early detection, education, and support services to those affected by breast cancer. A recipient of Charity Navigator's highest 4-star rating for 14 years, NBCF provides support through their National Mammography Program, Patient Navigation, breast health education, and patient suppor...

This interview has been conducted in partnership with the National Breast Cancer Foundation (NBCF). Recognized as one of the leading breast cancer organizations in the world, NBCF is Helping Women Now® by providing early detection, education, and support services to those affected by breast cancer. A recipient of Charity Navigator's highest 4-star rating for 14 years, NBCF provides support through their National Mammography Program, Patient Navigation, breast health education, and patient suppor...

This interview has been conducted in partnership with the National Breast Cancer Foundation (NBCF). Recognized as one of the leading breast cancer organizations in the world, NBCF is Helping Women Now® by providing early detection, education, and support services to those affected by breast cancer. A recipient of Charity Navigator's highest 4-star rating for 14 years, NBCF provides support through their National Mammography Program, Patient Navigation, breast health education, and patient suppor...

This interview has been conducted in partnership with the National Breast Cancer Foundation (NBCF). Recognized as one of the leading breast cancer organizations in the world, NBCF is Helping Women Now® by providing early detection, education, and support services to those affected by breast cancer. A recipient of Charity Navigator's highest 4-star rating for 14 years, NBCF provides support through their National Mammography Program, Patient Navigation, breast health education, and patient suppor...

This interview has been conducted in partnership with the National Breast Cancer Foundation (NBCF). Recognized as one of the leading breast cancer organizations in the world, NBCF is Helping Women Now® by providing early detection, education, and support services to those affected by breast cancer. A recipient of Charity Navigator's highest 4-star rating for 14 years, NBCF provides support through their National Mammography Program, Patient Navigation, breast health education, and patient suppor...

This interview has been conducted in partnership with the National Breast Cancer Foundation (NBCF). Recognized as one of the leading breast cancer organizations in the world, NBCF is Helping Women Now® by providing early detection, education, and support services to those affected by breast cancer. A recipient of Charity Navigator's highest 4-star rating for 14 years, NBCF provides support through their National Mammography Program, Patient Navigation, breast health education, and patient suppor...

This interview has been conducted in partnership with the National Breast Cancer Foundation (NBCF). Recognized as one of the leading breast cancer organizations in the world, NBCF is Helping Women Now® by providing early detection, education, and support services to those affected by breast cancer. A recipient of Charity Navigator's highest 4-star rating for 14 years, NBCF provides support through their National Mammography Program, Patient Navigation, breast health education, and patient suppor...

Oncology Data Advisor™ · Perspectives on Metastatic and Castration-Resistant Prostate Cancer With Ulka Vaishampayan, MD Selma Khenissi, MPS: Hello, welcome to Oncology Data Advisor. I'm Selma Khenissi from i3 Health. In honor of prostate cancer awareness month, we are here today with Dr. Ulka Vaishampayan, who will be discussing issues surrounding prostate cancer. Welcome. Ulka Vaishampayan, MD: Thank you for having me on this interview. I would like to bring our problems surroundin...

This interview has been conducted in partnership with the National Breast Cancer Foundation (NBCF). Recognized as one of the leading breast cancer organizations in the world, NBCF is Helping Women Now® by providing early detection, education, and support services to those affected by breast cancer. A recipient of Charity Navigator's highest 4-star rating for 14 years, NBCF provides support through their National Mammography Program, Patient Navigation, breast health education, and patient suppor...

This podcast has been conducted in partnership with the National Breast Cancer Foundation (NBCF). Recognized as one of the leading breast cancer organizations in the world, NBCF is Helping Women Now® by providing early detection, education, and support services to those affected by breast cancer. A recipient of Charity Navigator's highest 4-star rating for 14 years, NBCF provides support through their National Mammography Program, Patient Navigation, breast health education, and patient sup...

Keira Smith: Welcome to Oncology Data Advisor. I'm Keira Smith. Today I'm here with Dr. Thomas Abrams, the new Editor in Chief of Oncology Data Advisor. Thomas Abrams, MD: My name is Tom Abrams. I'm a gastrointestinal (GI) medical oncologist at Dana-Farber Cancer Institute. I've been there since 2006, and I see patients and engage in clinical research. It's been a wonderful career for me there. I'm really excited to be Editor in Chief of Oncology Data Advisor. This is a really fantastic online j...

Keira Smith: Welcome to Oncology Data Advisor, where we explore the latest advances in cancer research and treatment. I'm Keira Smith. In this podcast, Allison Imahiyerobo, nurse practitioner at Hematology/Oncology Physicians of Englewood, will be discussing strategies to optimize the management of patients with immune thrombocytopenia. Thank you for joining us! Allison Imahiyerobo, APN: Hi Keira, my name is Alli Imahiyerobo. I'm a nurse practitioner, and I practice at Hematology Oncology Physic...

Welcome to Oncology Data Advisor, where we explore the latest advances in cancer research and treatment. I'm Keira Smith. In this podcast, Dr. Steven Horwitz from Memorial Sloan Kettering Cancer Center will be discussing recent advances in the treatment of T-cell lymphoma. Thank you for joining us, Dr. Horwitz. Steven Horwitz, MD: Hi, pleasure to be here. I'm Dr. Steven Horwitz. I'm a medical oncologist at Memorial Sloan Kettering Cancer Center. Keira Smith: What do you consider some of the most...

· Keira Smith: Welcome to Oncology Data AdvisorTM, where we explore the latest advances in cancer research and treatment. I'm Keira Smith. In this podcast, Dr. Sara Tolaney from Dana-Farber Cancer Institute will be discussing strategies for improving the management of patients with metastatic breast cancer. Thank you for joining us, Dr. Tolaney. Sara Tolaney, MD, MPH: Thanks so much for having me. I'm Sara Tolaney. I'm a breast medical oncologist at Dana-Farber Cancer Institute here in Bo...

Welcome to Oncology Data Advisor, where we explore the latest advances in cancer research and treatment. I am Selma Khenissi from i3 Health. In this podcast, Dr. Kelly Brassil, PhD, RN, from The University of Texas MD Anderson Cancer Center, will be discussing patient-reported symptom data and how it affects patient survival and quality of life. Selma Khenissi, MPS: Can you comment on how tools such as Project Patient Voice positively impact the outcomes of patients with classical Hodgkin lympho...